Skip to content
Riskpilot
← Back to search
Sign in
Get full access
Shire Human Genetic Therapies AB
AB
Dissolved
Org 5565911764
Wholesale of pharmaceutical and medical goods
· NACE 4646
Est. 2000
3 employees
Watchlist
Share
Sweden
/
Companies
/
Wholesale of pharmaceutical and medical goods
/
Shire Human Genetic Therapies AB
Overview
Financials
People & ownership
Related companies
Loading company…
Financials
Revenue
SEK millions
0M
20M
39M
59M
78M
68M
2021
4M
2022
0M
2023
0M
2024
0M
2025
EBITDA
SEK millions
0M
1M
1M
2M
2M
2M
2021
0M
2022
1M
2023
1M
2024
0M
2025
Income statement
SEK thousands
Item
2021
2022
2023
2024
2025
Revenue
68 080
3 914
0
0
0
Staff expenses
—
—
—
—
—
EBITDA
1 702
95
822
965
476
Depreciation & amort.
−0
−0
−0
−0
−0
EBIT
1 702
95
822
965
476
Net financials
−36
—
—
—
—
Profit before tax
1 666
95
822
965
476
Tax
−374
−22
−170
−193
−122
Net profit
1 292
73
652
772
354
Balance sheet
SEK thousands
Item
2021
2022
2023
2024
2025
Total assets
24 654
24 730
25 546
26 506
26 653
Equity
24 646
24 720
25 372
26 144
26 498
Long-term debt
0
0
0
0
0
Short-term debt
8
10
175
363
156
Total debt
8
10
175
363
156
Financial ratios
5-year trend
EBITDA margin
47600000.0%
This company
15.8%
Market median
+301265723% vs market
2021
2025
Equity ratio
99.4%
This company
38.2%
Market median
+160% vs market
2021
2025
Return on equity
1.3%
This company
18.4%
Market median
-93% vs market
2021
2025
Net profit margin
35400000.0%
This company
8.1%
Market median
+437036937% vs market
2021
2025
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
2021
2025
Debt / equity
0.01×
This company
0.62×
Market median
+98% vs market
2021
2025
Annual reports & filings
Annual report 2025
Filed via Bolagsverket / SCB · Period 2024-04-01 – 2025-03-31
View
PDF
Annual report 2024
Filed via Bolagsverket / SCB · Period 2023-04-01 – 2024-03-31
View
PDF
Annual report 2023
Filed via Bolagsverket / SCB · Period 2022-04-01 – 2023-03-31
View
PDF
Annual report 2022
Filed via Bolagsverket / SCB · Period 2021-04-01 – 2022-03-31
View
PDF
Annual report 2021
Filed via Bolagsverket / SCB · Period 2020-04-01 – 2021-03-31
View
PDF
More on Shire Human Genetic Therapies AB
Overview →
Headline figures, risk assessment and company summary
People & ownership →
Management, board and shareholder breakdown
Related companies →
Corporate hierarchy, parent and subsidiary network
Riskpilot